For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, DiaMedica Therapeutics Inc (NASDAQ: DMAC) closed at $9.12 up 1.00% from its previous closing price of $9.03. In other words, the price has increased by $1.00 from its previous closing price. On the day, 0.82 million shares were traded. DMAC stock price reached its highest trading level at $9.23 during the session, while it also had its lowest trading level at $8.8.
Ratios:
For a deeper understanding of DiaMedica Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.67 and its Current Ratio is at 10.67. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
On October 07, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $7.H.C. Wainwright initiated its Buy rating on October 07, 2024, with a $7 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 25 ’25 when STAHLBERG JAN bought 338,265 shares for $6.00 per share. The transaction valued at 2,029,252 led to the insider holds 7,654,045 shares of the business.
STAHLBERG JAN bought 293,601 shares of DMAC for $1,734,918 on Aug 13 ’25. The 10% Owner now owns 7,058,066 shares after completing the transaction at $5.91 per share. On Aug 14 ’25, another insider, STAHLBERG JAN, who serves as the 10% Owner of the company, bought 70,414 shares for $5.99 each. As a result, the insider paid 421,921 and bolstered with 7,128,480 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DMAC now has a Market Capitalization of 474946240 and an Enterprise Value of 419894240.
Stock Price History:
The Beta on a monthly basis for DMAC is 1.27, which has changed by 0.61273205 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, DMAC has reached a high of $9.20, while it has fallen to a 52-week low of $3.19. The 50-Day Moving Average of the stock is 32.72%, while the 200-Day Moving Average is calculated to be 72.55%.
Shares Statistics:
For the past three months, DMAC has traded an average of 407.44K shares per day and 736410 over the past ten days. A total of 52.08M shares are outstanding, with a floating share count of 23.83M. Insiders hold about 52.82% of the company’s shares, while institutions hold 24.91% stake in the company. Shares short for DMAC as of 1763078400 were 5004442 with a Short Ratio of 12.28, compared to 1760486400 on 4118787. Therefore, it implies a Short% of Shares Outstanding of 5004442 and a Short% of Float of 13.819999999999999.
Earnings Estimates
Investors are keenly observing as 4.0 analysts analyze and rate. The current performance of DiaMedica Therapeutics Inc (DMAC) in the stock market.The consensus estimate for the next quarter is -$0.19, with high estimates of -$0.18 and low estimates of -$0.22.
Analysts are recommending an EPS of between -$0.7 and -$0.74 for the fiscal current year, implying an average EPS of -$0.72. EPS for the following year is -$0.76, with 5.0 analysts recommending between -$0.6 and -$0.9.
